Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Ahmad-Samer Al-Homsi, Sebastien Anguille, Dries Deeren, Taiga Nishihori, Nathalie Meuleman, Maher Abdul-Hay, Gareth J. Morgan, Jason Brayer, Nathalie Braun, Caroline Lonez, Marie-Sophie Dheur, Erik Alcantar-Orozco, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2021-147738

Published: 2021

Journal Articles

Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS

Dries Deeren, Johan A. Maertens, Tara L. Lin, Yves Beguin, Erik Alcantar-Orozco, Marie-Sophie Dheur, Eytan Breman, Nathalie Braun, Caroline Lonez, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 408.

https://doi.org/10.1182/blood-2021-152413

Published: 2021

Journal Articles

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Dries Deeren, MD PhD, Johan A. Maertens, MD PhD, Tara Lin, MD, Yves Beguin, MD PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD, Eytan Breman, Marie-Sophie Dheur, PhD PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-139667

Published: 2020

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

A. Samer Al-Homsi, MD, Sebastien Anguille, MD, Jason Brayer, PhDMD, Dries Deeren, MD PhD, Nathalie Meuleman, PhD MD, Gareth Morgan, MDPhDFRCP, Taiga Nishihori, MD, Panagiota A. Sotiropoulou, PhD, Laure Twyffels, PhD, Jennifer Bolsee, PhD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139516

Published: 2020

Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2018-99-114747

Published: 2018

Journal Articles

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

David A Sallman, MD, Tessa Kerre, MD, Xavier Poire, MD, Violaine Havelange, Philippe Lewalle, MD, Marco L. Davila, MD PhD, Eunice S. Wang, MD, Doreen Dekker, PhD, Sarah Snykers, PhD, Panagiota A. Sotiropoulou, PhD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, Bikash Verma, MD DVM, Frédéric F. Lehmann, MD, Jason B. Brayer, PhDMD

Blood (2018) 132 (Supplement 1): 902.

https://doi.org/10.1182/blood-2018-99-111326

Published: 2018

NARROW

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only